Corient IA’s GSK GSK Stock Holding History

Corient IA’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$329K	Hold	5,970	–	–	0.31%	121
2025 Q4	$293K	Sell	5,970 -4,030	-40%	-$188K	0.28%	154
2025 Q3	$432K	Sell	10,000 -5,000	-33%	-$195K	0.32%	122
2025 Q2	$576K	Hold	15,000	–	–	0.34%	96
2025 Q1	$581K	Buy	+15,000	New	+$549K	0.41%	79

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Corient IA's GSK Position: Q1 2026 in Review

Corient IA held its GSK (GSK) position steady in Q1 2026 at 5,970 shares worth $329K. The position accounts for 0.31% of the portfolio, ranked #121.

Corient IA first reported a position in GSK in Q1 2025 and has held it in 5 quarters since. The position peaked at $581K in Q1 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Corient IA held 5,970 shares of GSK worth $329K as of Q1 2026.
Corient IA left its GSK share count unchanged in Q1 2026.
GSK made up 0.31% of Corient IA's portfolio in Q1 2026, its #121 holding.
Corient IA first reported a position in GSK in Q1 2025 and has held it in 5 quarters since.
Corient IA's GSK position peaked at $581K in Q1 2025.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Corient IA's 13F filing for Q1 2026, filed 14 May 2026.